ArticleJournal of veterinary internal medicine2026
The effect of ertugliflozin on serum insulin and glucose in healthy horses receiving dexamethasone.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSodium-glucose cotransporter 2 inhibitors (SGLT-2i) can be used to manage insulin dysregulation (ID). Their effect on corticosteroid-induced ID is unknown. HYPOTHESIS/
objectivesEvaluate effects of ertugliflozin on serum insulin and glucose concentrations in horses receiving dexamethasone (DEX). We hypothesized that DEX would induce ID and ertugliflozin coadministration would mitigate that effect. ANIMALS: Seven healthy horses.
methodsRandomized crossover design; horses received DEX (0.06 mg/kg IV q48h; DEX)or ertugliflozin (0.05 mg/kg PO q24h) plus DEX (SGLT-2i group) for seven days. Oral sugar (OST) and insulin tolerance (ITT) tests were performed before and after treatment. Insulin and glucose concentrations were measured during treatment. Data were analyzed using mixed-effects linear models.
resultsMean daily insulin concentrations were lower in the SGLT-2i compared with the DEX group (P < .001), with a block effect-mean insulin (95% CI) μIU/mL: Block 1 DEX 50.6 (42.1-59.1) and SGLT-2i 35.9 (28.1-43.7); Block 2 DEX 34.5 (27.8-41.3) and SGLT-2i 18.9 (16.5-21.4). Glucose was lower in the SGLT-2i group on days 3 and 5 (P < .001)-mean glucose (95% CI) mg/dL: Day 3 DEX 117.3 (110.4-124.3) and SGLT-2i 101.0 (95.7-106.4); Day 5 DEX 116.6 (107.9-125.3) and SGLT-2i 101.0 (95.5-106.4). Post-treatment OST insulinT60 was higher in both groups (P = .01). Glucose concentrations decreased less during the ITT post-treatment in the SGLT-2i group compared with DEX (P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Ertugliflozin lowered mean daily serum insulin concentrations in horses receiving DEX. Dynamic tests after drug discontinuation did not indicate ID improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.